Recent studies have demonstrated tremendous diversity in the genetic makeup of metastatic castration-resistant prostate cancer (mCRPC). The SU2C−Prostate Cancer Foundation (PCF) Prostate Dream Team is sequencing patient DNA and systematically comparing it with patient response to therapies. The aim is to identify biomarkers and predictors that will help physicians determine the best treatments for patients based on their molecular profiles.